Athera Biotechnologies announces that a composition of matter patent covering antibodies with binding to phosphorylcholine, PC has been allowed by the European Patent Office, EPO. The PC target is part of modified phospholipids and has been characterized as an active driver of vascular inflammatiAlready a subscriber Login You have read…